NICE publishes positive final guidance on Entyvio® (vedolizumab)

NICE recommends vedolizumab as an option for adults with moderately to severely active Crohn’s Disease (CD) who have either failed,* or were intolerant or contraindicated to, a tumour necrosis factor alpha inhibitor (anti-TNF) (1)
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Practical therapeutics Legislation & regulation Gastroenterology anti-TNF crohn's disease Latest News NICE guidance ulcerative colitis vedolizumab Source Type: news